Ixico Plc · LSE:IXI

Ixico — Investor Day (October 2025)

53 slides from Ixico's investor day presentation, Oct 30, 2025

Slide 1: IXICO plc Capital Markets Day
IXICO plc Capital Markets Day 30 October 2025 www.ixico.com CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl
Slide 3: Agenda
Agenda 14:00 James Chandler Welcome and introduction (5 minutes) Chief Business Officer 14:05 Bram Goorden COMPANY PRESENTATION: Growth strategy and future direction (30 minutes) Chief Executive Officer Grant Nash Chief Financial Officer/Chief Operating Officer 14:35 Robin Wolz SCIENTIFIC PRESENTATI
Slide 4: Company: Growth strategy and future direction
COMPANY Growth strategy and future direction Bram Goorden, CEO Grant Nash, CFO/COO CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 6: The opportunity to advance CNS research and treatment
The opportunity to advance CNS research and treatment has never been more exciting… …as the market re-prioritizes CNS research, embracing AI-driven R&D approaches will be critical in increasing previously challenging treatment success rates. 6 CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 7: Who are IXICO?
Who are IXICO? >90 employees (27% PhDs) 26 current studies with… The leading iCRO focussed exclusively on CNS 17 leading global pharma, biotech & diagnostics Co’s 20 years of neuroscience >1,250 imaging centres around the world utilising the IXI expertise delivering gold standard technology platform
Slide 8: Meet the team
Meet the team Board Members Deepened expertise focussed CEO Mark Warne Dipti Amin Kate Rogers on global footprint expansion (Chair) (NED) (NED) and revenue growth Bram Goorden* Existing roles Expanded roles New roles HR Legal QA/RA CFO / COO CSO / CMO CTO CBO Hannah Annamaria John Grant Robin Mark J
Slide 9: What impact does IXICO make?
What impact does IXICO make? ALZHEIMER’S HUNTINGTON’S BLOOD BASED DISEASE DISEASE BIOMARKER IXICO confirmed as imaging partner in Phase I/II clinical trial for novel gene Validation of a blood test to diagnose GAP Bio-Hermes II trial therapy to treat HD Alzheimer’s for FDA clearance CAPITAL MARKETS
Slide 10: Why is this the right time for IXICO?
Why is this the right time for IXICO? 13% revenue increase to £6.5m (FY24: £5.8m) £1.6m EBITDA loss (FY24: £1.7m) £3.5m cash (FY24: £1.8m) £10.5m market cap 28% share price uplift 10 CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 11: The societal challenge and opportunity
The societal challenge and opportunity +1716% Global Data, 2025 x18 20yr (2004-2024) Global Data, 2025 43% of the global population affected by neurological disorders.* 3.4bn people and expected to grow by 22% to 4.9bn by 2050** 7% (CAGR) global clinical trial imaging market growth to $1.91 bn (2030
Slide 12: IXICO's unique proposition to meet that opportunity
IXICO’s unique proposition to meet that opportunity Alzheimer's Disease IXICO AI PLATFORM Imaging biomarkers Huntington's Disease Drug safety Multiple Sclerosis Patient Parkinson's Trial management Disease eligibility Other: Demyelinating IXICO EXPERTISE Drug Disorders efficacy Other: Parkinsonian D
Slide 13: 'Innovate Lead Scale' Strategy – Driving value
'Innovate Lead Scale’ Strategy – Driving value INNOVATE Product differentiation Technology expansion Disease diversification ACCELERATE REVENUE GROWTH LEAD Market visibility Global footprint INCREASE VALUE SCALE OB/Revenue growth Expand serviceable market New revenue streams CAPITAL MARKETS DAY 2025
Slide 14: 'Innovate Lead Scale' Strategy – FY25 investments & outcomes
'Innovate Lead Scale’ Strategy – Driving value RAG FY25 investments & outcomes New AD/PD product offerings INNOVATE Deployment of next gen IXI Product differentiation TA diversification Technology expansion Disease diversification Novel IXI applications & revenues ACCELERATE REVENUE Heightened confe
Slide 15: 'Innovate Lead Scale' Strategy – FY25 trading traction
'Innovate Lead Scale’ Strategy – FY25 trading traction 8 Oct-25 FY trading update Revenue EBITDA loss Cash 13% revenue increase to £6.5m 6 (FY24: £5.8m) 4 £1.6m EBITDA loss £ million (FY24: £1.7m) 2 £3.5m cash (FY24: £1.8m) 0 £13.8m order book (H1-25: £13.1m) -2 -4 2024 2025 Financial year CAPITAL M
Slide 16: 'Innovate Lead Scale' Strategy – Commercial impact
'Innovate Lead Scale’ Strategy – Commercial impact Investment • Fund raise £3.7m (net of fees) • 8 additional scientific, commercial & US-based FTEs • AD data rights accessed • Differentiated analysis pipelines developed • New KOL partnerships in AD & PD Impact • IXI launched • 37 projects supported
Slide 17: 'Innovate Lead Scale' Strategy – Order book diversity
'Innovate Lead Scale’ Strategy – Order book diversity Pipeline within the order book* 25 projects - £m by clinical trial phase 25 projects - £m by therapeutic indication (no.#) (no.#) £2.4m £2.1m Phase 1 (4) (5) £3.5m (9) Phase 2 Huntington's £1.5m £6.6m Alzheimer's Phase 3 (2) (10) £0.5m Parkinson'
Slide 18: Targeting £10m revenue in medium term
'Innovate Lead Scale’- targeting £10m revenue in medium term FY26 bookings expansion – transforming the order book *Estimated by Mgmt. based on bottom-up review of clinical trial start ups over a 12–18-month period (Source: GlobalData) Outcome Revenue growth | Reduced losses |Increased order book Se
Slide 19: 'Innovate Lead Scale' Strategy – New revenue streams
'Innovate Lead Scale’ Strategy – New revenues streams Current CLINICAL TRIALS– Biopharma R&D insights applications Innovate Lead Scale POST MARKET SURVEILLANCE AUTOMATION & INTEGRATION Licensing | Strategic Investments | Partnerships IXICO AI PLATFORM Multi- Large data Large scale Imaging Platform B
Slide 20: Leveraging IXI – Moving beyond £10m revenues
Leveraging IXI – Moving beyond £10m revenues Revenues via multimodal strategy Market Value & Revenues to accelerate double digit growth Techbio Model Expansion of multimodal model (incl. iCRO growth activity) iCRO+ Expansion of existing verticals FY25 FY26 FY27 FY28 FY29 FY30 30/09/25 30/09/26 30/09
Slide 21: Potential to achieve more progress in CNS research in next 5 years
There is the potential to achieve more progress in CNS research over the next 5 years than in the previous 50… IXICO has spent the last 20 years building towards this moment and is poised for profitable growth… …it is IXICO’s technology that will drive this growth CAPITAL MARKETS DAY 2025 | © IXICO
Slide 22: Why is this the right time for IXICO?
Why is this the right time for IXICO? Growing revenues Moving to profitability Increasing value 22 CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 23: Science: The neuroscience landscape & scientific roadmap
SCIENCE The neuroscience landscape & scientific roadmap Robin Wolz, CSO/CMO CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 24: Neurology - progressing rapidly towards precision medicine
Neurology - progressing rapidly towards precision medicine Significant momentum towards biomarker use across relevant therapeutic indications 18x increase https://www.thebusinessresearchcompany.com/market-insights/biomarker-clinical- GlobalData, 2025 phase-outsourcing-services-market-overview-2025 C
Slide 25: Biomarker use momentum – Alzheimer's Disease
Biomarker use momentum – Alzheimer’s Disease AD – “ATN” biomarker model (2010) Biomarker use is well established in diagnostic criteria and trial designs Jack et al, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade; Lancet Neurology, 9(1):119-28; 2010 CAPITAL MARKETS
Slide 26: Using biomarkers to move from a one size fits all approach
Using biomarkers to move from a one size fits all approach HD: “HD-ISS” biomarker model (2022) PD: “NSD-ISS” biomarker model (2024) Tabrizi et al, A biological classification of Huntington's disease: the Integrated Staging System; Simuni et al, A biological definition of neuronal α-synuclein disease
Slide 27: Alzheimer's Disease – FDA approved therapy momentum
Alzheimer’s Disease – FDA approved therapy momentum 3 anti-amyloid disease modifying therapies now approved (Lilly, Biogen and Eisai) 138 strong drug development pipeline GLP-1 receptor agonist potential FDA’s 2024 early AD draft guidance encourages biomarker use across trial stages Reduction in amy
Slide 28: Parkinson's Disease – the next frontier
Parkinson’s Disease – the next frontier Moving towards disease modifying therapies Imaging is a critical and expanding biomarker >130 drugs in clinical development Cautious optimism as Roche enters Phase III • Positive trend in clinical benefit and biomarker effect (neuromelanin MRI) CAPITAL MARKETS
Slide 29: Huntington's Disease – treatment breakthroughs
Huntington’s Disease – treatment breakthroughs uniQure gene therapy slows disease Novartis $2.9bn licensing agreement with PTC Therapeutics Wave drug entering registrational trial IXICO-led HD-IH consortium defining implementation of imaging biomarkers for clinical trials CAPITAL MARKETS DAY 2025 |
Slide 30: IXICO scientific roadmap – pioneering biomarkers
IXICO scientific roadmap – pioneering biomarkers Vascular World class Neuromelanin abnormalities ID & measurement AD HD data HD measurement PD AD Multi access FURTHER FURTHER VASCULAR NEUROMELANIN HD-IH DATA SET VASCULAR INFLAMMATION BIOMARKER #1 BIOMARKER BIOMARKERS MEASUREMENTS 2025 2026 55-80% of
Slide 31: AD - Establishing vascular MRI standards on IXI
AD - Establishing vascular MRI standards on IXI Platform STRIVE-2 Standards LANDMARK PAPER* - Neuroimaging standards for research into small vessel disease—advances since 2013* * Lancet Neurology 2023: 22:602-18 May 23, 2023 New MRI techniques IXI On IXI run on AD trials Committed on IXICO roadmap
Slide 32: PD - Measuring neuromelanin loss is important
PD - Measuring neuromelanin loss is important Pyatigorskaya et al. Am J Neuror. 2018
Slide 33: PD - IXICO accurately measures neuromelanin loss
PD - IXICO accurately measures neuromelanin loss Image before IXICO processing IXICO-processed Image 33
Slide 34: IXICO at the forefront of precision medicine in neurological disease
IXICO at the forefront of precision medicine in neurological disease Significant momentum in key IXICO therapeutic indications IXICO’s biomarker progress is well suited to better define, diagnose and treat disease IXI and forthcoming scientific Platform products are well positioned to support a new
Slide 35: Fireside chat: Trends in the treatment of Alzheimer's disease
FIRESIDE CHAT Trends in the treatment of Alzheimer's disease Prof. Mike Weiner, UCSF & founder/principal investigator Alzheimer’s Disease Neuroimaging Initiative Robin Wolz, CSO/CMO CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 38: Fireside chat: The pharmaceutical view
FIRESIDE CHAT The pharmaceutical view Johannes Streffer, SVP Global Clinical Development, Lundbeck Bram Goorden, CEO CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 39: Technology: The IXI Platform & technology roadmap
TECHNOLOGY The IXI Platform & technology roadmap Mark Austin, CTO CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 40: pi Backlog (16) UATD-23372-Baseline-CNN Putamen Endpoint QC
pi Backlog (16) UATD-23372-Baseline-CNN Putamen Endpoint QC Backlog Mybacklog Completed Data avery Status Priority Due date Start date Assigned to Uy: UALZ FIUZaAL 28 Hh Task overdue 25 Mar 2024 Lesha A Szulimowsk ‘Study site: UAT Assigned: Subject UATD-23372 Ho Event: Baseline Taskoverue ‘Study: UA
Slide 41: IXI an AI-enabled platform for precision medicine
IXI an AI-enabled platform for precision medicine Standardised capture, analysis and reporting Hospital/Site of regulatory compliant clinical data Client Pharma, Pharma /Biotech, Biotech MR images Diagnostic sponsor Co. Clinical development Support Drug and the development PET images diagnostic of d
Slide 42: IXI - data selection and acquisition
IXI - data selection and acquisition PURPOSE Secure, web-based capture of data across thousands of sites into the IXI Platform. BENEFIT • No local installation • Rapid qualification • Right data first time • Patient privacy guaranteed CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 43: IXI - high quality image capture
IXI - high quality image capture PURPOSE 3D & 4D data visualization to ensure quality control supported by automated metadata checks BENEFIT • Fast turnaround of high-quality data • High accuracy & reproducibility • Direct feedback scanner sites • Patient participation optimization CAPITAL MARKETS D
Slide 44: IXI - image reading
IXI - image reading PURPOSE Flexible radiology read dashboard BENEFIT • Dashboard of high-quality prequalified scans • Available anytime anywhere • Enables rapid image reading turnaround Prof. Frederik Barkhof, UCL, VUMC & IXICO SAB CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 45: Radiology Read
UTILITY • Flexible read workflows Radiology Read with bespoke read forms and web- based viewer VALUE • Our pool of expert readers are able to read on the platform anytime from anywhere • Rapid turnaround of central reads 45 BUSINESS USE ONLY © IXICO plc 2025
Slide 46: IXI - advanced AI analytics
IXI - advanced AI analytics PURPOSE AI analysis to generate precision disease insights at scale from complex data BENEFIT • Turning science into products • Integrated dashboard for visual review • Informs critical safety/efficacy decisions • Report/Review/Transfer Insights CAPITAL MARKETS DAY 2025 |
Slide 47: IXI - imaging capability
IXI - imaging capability Volumetric MRI – Measures neurodegeneration across >140 regions to track disease modifying drug effects Advanced MRI – Assesses white-matter integrity and brain network activity to detect early, subtle changes in brain function. PET - Visualizes amyloid and tau protein accum
Slide 48: IXI - engineered for scale
IXI - engineered for scale Powerful platform foundation built for flexibility, scale and expansion Platform extensions 3rd party pipelines Analysis Automation Bespoke Unmatched regulatory Flexible workflows compliance and security architecture CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 49: IXI - Platform expansion
IXI - Platform expansion Enabling a UK innovator to advance its global impact in precision healthcare. Agility Extensibility >AI CAPITAL MARKETS DAY 2025 | © IXICO PLC
Slide 50: IXI - mastering AI for impact
IXI - mastering AI for impact Artificial Machine Deep Generative Agentic Intelligence Learning Learning AI AI (c. 1950) (c. 1980) (c. 2012) (c. 2022) (c. 2024) Generative & Agentic AI drive IXICO Platform development efficiencies Innovation IXICO AI TRIAL AUTOMATION GEN AI NEW ANALYSIS ENDPOINTS DEE
Slide 51: Backlog -TiatTrackerNx valent next ntextUuid= babs
Backlog -TiatTrackerNx 8 valent next ntextUuid= babs Backlog (1) = 01-001-Predict MRI Report Helo, Demo ste (OR eee 22kcg Mybacklog Completed Status Priority Start date End date Completed by Re-assign to Data query tin 05 Dec 2024 Event: Screening ‘Study: MSA1_DEM24 01-001-Predict MRI Report ‘Study:
Slide 53: Closing comments
CLOSING COMMENTS Bram Goorden, CEO Julian Morse, CEO - Cavendish CAPITAL MARKETS DAY 2025 | © IXICO PLC

IXICO — Investor Day (October 2025) on 6ix

Ixico — Investor Day (October 2025)

Slide 1: IXICO plc Capital Markets Day

Slide 2: Nonregulated Disclaimer

Slide 3: Agenda

Slide 4: Company: Growth strategy and future direction

Slide 5: Neurology market: 5% CAGR

Slide 6: The opportunity to advance CNS research and treatment

Slide 7: Who are IXICO?

Slide 8: Meet the team

Slide 9: What impact does IXICO make?

Slide 10: Why is this the right time for IXICO?

Slide 11: The societal challenge and opportunity

Slide 12: IXICO's unique proposition to meet that opportunity

Slide 13: 'Innovate Lead Scale' Strategy – Driving value

Slide 14: 'Innovate Lead Scale' Strategy – FY25 investments & outcomes

Slide 15: 'Innovate Lead Scale' Strategy – FY25 trading traction

Slide 16: 'Innovate Lead Scale' Strategy – Commercial impact

Slide 17: 'Innovate Lead Scale' Strategy – Order book diversity

Slide 18: Targeting £10m revenue in medium term

Slide 19: 'Innovate Lead Scale' Strategy – New revenue streams

Slide 20: Leveraging IXI – Moving beyond £10m revenues

Slide 21: Potential to achieve more progress in CNS research in next 5 years

Slide 22: Why is this the right time for IXICO?

Slide 23: Science: The neuroscience landscape & scientific roadmap

Slide 24: Neurology - progressing rapidly towards precision medicine

Slide 25: Biomarker use momentum – Alzheimer's Disease

Slide 26: Using biomarkers to move from a one size fits all approach

Slide 27: Alzheimer's Disease – FDA approved therapy momentum

Slide 28: Parkinson's Disease – the next frontier

Slide 29: Huntington's Disease – treatment breakthroughs

Slide 30: IXICO scientific roadmap – pioneering biomarkers

Slide 31: AD - Establishing vascular MRI standards on IXI

Slide 32: PD - Measuring neuromelanin loss is important

Slide 33: PD - IXICO accurately measures neuromelanin loss

Slide 34: IXICO at the forefront of precision medicine in neurological disease

Slide 35: Fireside chat: Trends in the treatment of Alzheimer's disease

Slide 36: Q&A

Slide 37: Break

Slide 38: Fireside chat: The pharmaceutical view

Slide 39: Technology: The IXI Platform & technology roadmap

Slide 40: pi Backlog (16) UATD-23372-Baseline-CNN Putamen Endpoint QC

Slide 41: IXI an AI-enabled platform for precision medicine

Slide 42: IXI - data selection and acquisition

Slide 43: IXI - high quality image capture

Slide 44: IXI - image reading

Slide 45: Radiology Read

Slide 46: IXI - advanced AI analytics

Slide 47: IXI - imaging capability

Slide 48: IXI - engineered for scale

Slide 49: IXI - Platform expansion

Slide 50: IXI - mastering AI for impact

Slide 51: Backlog -TiatTrackerNx valent next ntextUuid= babs

Slide 52: Q&A

Slide 53: Closing comments